Orphanet: Eenvoudig zoeken

Zoek een klinische studie of trial

Andere zoekoptie(s)

226 Resultaat/Resultaten

Nationale klinische studie(s)

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU Institution: Information not provided - AU

MAGNET: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - BE UZ Leuven - Campus Gasthuisberg Dienst neurologie/ Department of Neurology

TUDCA-ALS OLE: Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study - BE UZ Leuven - Campus Gasthuisberg Dienst neurologie/ Department of Neurology

TUDCA-ALS: Veiligheid en werkzaamheid van TUDCA als aanvullende behandeling bij patiënten met ALS - BE UZ Leuven - Campus Gasthuisberg Dienst neurologie/ Department of Neurology

TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - DE- Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

KETO-ALS: Efficacy and Tolerability of Beta Hydroxybutyrate in Patients With Amyotrophic Lateral Sclerosis (ALS) Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

ADORE: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis -DE Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

COURAGE-ALS: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) -DE Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

COURAGE OLE: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) -DE Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

MERIDIAN: A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) -DE Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

ROCK-ALS: Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS -DE- Klinikum rechts der Isar der Technischen Universität München Neurologische Klinik und Poliklinik

TUDCA-ALS OLE: Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study -DE Charité - Universitätsmedizin Berlin (CVK) Klinik für Neurologie mit Experimenteller Neurologie (CVK)

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - DE Universitätsklinikum Münster Centrum für seltene Erkrankungen (ZSE) Münster

Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis - FR Institution: Information not provided - FR

TUDCA-ALS OLE: Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study -FR Institution: Information not provided - FR

TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - FR Institution: Information not provided - FR

FAIR-ALS II: Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone CHRU de Lille - Hôpital Roger Salengro Service de Neurologie B

MD1003-ALS : Effect of MD1003 in Amyotrophic Lateral Sclerosis: a Randomized Double Blind Placebo Controlled Pilot Study (Phase II) CHU de Montpellier - Hôpital Gui de Chauliac Clinique du Motoneurone et Pathologies neuromusculaires

ROCK-ALS: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS - FR CHU de Montpellier - Hôpital Gui de Chauliac Clinique du Motoneurone et Pathologies neuromusculaires

TRIALS Protocol: A Double-blind, Placebo-controlled, Exploratory Randomised Clinical Trial to Assess the Safety and Efficacy of IFB-088 Plus Riluzole 100 mg vs Placebo Plus Riluzole 100 mg in Patients With Bulbar-onset Amyotrophic Lateral Sclerosis -FR CHU de Marseille - Hôpital de la Timone

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS - IE Institution: Information not provided - IE

Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)-IE Institution: Information not provided - IE

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002-IE Institution: Information not provided - IE

TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE Trinity College Dublin Research Motor Neurone - Trinity Biomedical Sciences Institute

Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300 Institution: Information not provided - IL

Efficacy and safety of treatment with miglustat in patients with Niemann-Pick disease type c Azienda Ospedaliera Universitaria "Federico II" Laboratorio Dipartimento di Pediatria

Efficacy safety and tolerability of growth hormone in patients with amyotrophic lateral sclerosis as add-on therapy to Riluzole-Phase II Azienda Ospedaliera Universitaria "Federico II" AOU Federico II

ALD-104 - A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects 0 to 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) - IT IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO U.O. di Oncoematologia

Efficacy of Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS) Policlinico Universitario Campus Bio-Medico U.O.C. Neurologia

Tolerability, Safety and Efficacy of Sigh During Non-invasive Mechanical Ventilation in Patients With Motor Neuron Disease - A Pilot Study IRCCS Ospedale San Raffaele U.O. di Neurologia

A Phase II, Randomised, Double-Blind, Placebo-Controlled Study Followed by a Continuing Open Label Study, to Verify the Efficacy and Safty of Intrathecal Administration of KP-100IT using NP022 in Subjects with Amyotrophic Lateral Sclerosis (ALS) Institution: Information not provided - JP

Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS - NL UMC Utrecht - Universitair Medisch Centrum Utrecht Polikliniek Neuromusculaire Ziekten

HORIZON: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy - AT Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy - AT Institution: Information not provided - AT

Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells Zaklad Patologii Ogolnej

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK Institution: Information not provided - SK

MAGNET: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) -ES Hospital Universitari de Bellvitge

IMCRELA: Impact of the combined treatment of the liposomated polyphenols curcula and resveratrol with dutasteride, in the clinical improvement of patients with ALS treated with riluzole -ES Universidad Católica de Valencia San Vicente Mártir Clínicas UCV

Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With Dutasteride on the Clinical Improvement of ALS Patients -ES Universidad Católica de Valencia San Vicente Mártir Facultad de Enfermería

OAK: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic Failure - ES Institution: Information not provided - ES

MERIDIAN: A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) -ES Institution: Information not provided - ES

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation - ES Institution: Information not provided - ES

Phoenix: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) -ES Institution: Information not provided - ES

ADORE: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis - ES Institution: Information not provided - ES

A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia) - ES Institution: Information not provided - ES

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis -ES Institution: Information not provided - ES

A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) -ES Institution: Information not provided - ES

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy -ES Institution: Information not provided - ES

ADOREXT: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis -ES Institution: Information not provided - ES

HIMALAYA: A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension -ES Institution: Information not provided - ES

CARDINALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis -ES Institution: Information not provided - ES

TCIM-ELAII: Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosis -ES Hospital Clínico Universitario Virgen de la Arrixaca Servicio de Hematología

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis - US University of Kansas Medical Center Research Institute

Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History (Phase I) - US Mayo Clinic Rochester

Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS Institution: Information not provided - US

Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure Institution: Information not provided - US

Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS Currently Taking Riluzole Institution: Information not provided - US

A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Institution: Information not provided - US

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Institution: Information not provided - US

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Institution: Information not provided - GB

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB Institution: Information not provided - GB

A Phase II Pilot Single-arm Safety and Tolerability Study of ILB in Patients With Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS) -GB University of Birmingham Institute for cancer studies

MAGNET: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - SE Institution: Information not provided - SE

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral Sclerosis - SE Karolinska Institutet Department of Clinical Neuroscience (CNS)

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - CH Universitätsspital Inselspital University Hospital Inselspital

ROCK-ALS : Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS - CH Kantonsspital St. Gallen Muskelzentrum/ ALS clinic

A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -AU Institution: Information not provided - AU

A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -GB Institution: Information not provided - AU

PIVOT-HD: A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -DE Universitäts- und Rehabilitationskliniken Ulm (RKU) Klinik für Neurologie

Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements -DE Institution: Information not provided - DE

DIAN-TU: A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-part Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease -DE Institution: Information not provided - DE

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE Universitätsmedizin Göttingen Klinik für Kinder- und Jugendmedizin

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease -DE Universitäts-Kinderklinik am St. Josef-Hospital CeSER - Centrum für Seltene Erkrankungen (ZSE) der Ruhr-Universität Bochum

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -FR Institution: Information not provided - FR

A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -FR Institution: Information not provided - FR

Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements -FR Institution: Information not provided - FR

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU
Institution: Information not provided - AU

MAGNET: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - BE
UZ Leuven - Campus Gasthuisberg

Dienst neurologie/ Department of Neurology

TUDCA-ALS OLE: Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study - BE
UZ Leuven - Campus Gasthuisberg

Dienst neurologie/ Department of Neurology

TUDCA-ALS: Veiligheid en werkzaamheid van TUDCA als aanvullende behandeling bij patiënten met ALS - BE
UZ Leuven - Campus Gasthuisberg

Dienst neurologie/ Department of Neurology

TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - DE-
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

KETO-ALS: Efficacy and Tolerability of Beta Hydroxybutyrate in Patients With Amyotrophic Lateral Sclerosis (ALS)
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

ADORE: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis -DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

COURAGE-ALS: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) -DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

COURAGE OLE: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) -DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

MERIDIAN: A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) -DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

ROCK-ALS: Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS -DE-
Klinikum rechts der Isar der Technischen Universität München

Neurologische Klinik und Poliklinik

TUDCA-ALS OLE: Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study -DE
Charité - Universitätsmedizin Berlin (CVK)

Klinik für Neurologie mit Experimenteller Neurologie (CVK)

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - DE
Universitätsklinikum Münster

Centrum für seltene Erkrankungen (ZSE) Münster

Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis - FR
Institution: Information not provided - FR

TUDCA-ALS OLE: Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study -FR
Institution: Information not provided - FR

TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - FR
Institution: Information not provided - FR

FAIR-ALS II: Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
CHRU de Lille - Hôpital Roger Salengro

Service de Neurologie B

MD1003-ALS : Effect of MD1003 in Amyotrophic Lateral Sclerosis: a Randomized Double Blind Placebo Controlled Pilot Study (Phase II)
CHU de Montpellier - Hôpital Gui de Chauliac

Clinique du Motoneurone et Pathologies neuromusculaires

ROCK-ALS: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS - FR
CHU de Montpellier - Hôpital Gui de Chauliac

Clinique du Motoneurone et Pathologies neuromusculaires

TRIALS Protocol: A Double-blind, Placebo-controlled, Exploratory Randomised Clinical Trial to Assess the Safety and Efficacy of IFB-088 Plus Riluzole 100 mg vs Placebo Plus Riluzole 100 mg in Patients With Bulbar-onset Amyotrophic Lateral Sclerosis -FR
CHU de Marseille - Hôpital de la Timone

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS - IE
Institution: Information not provided - IE

Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)-IE
Institution: Information not provided - IE

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002-IE
Institution: Information not provided - IE

TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE
Trinity College Dublin

Research Motor Neurone - Trinity Biomedical Sciences Institute

Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
Institution: Information not provided - IL

Efficacy and safety of treatment with miglustat in patients with Niemann-Pick disease type c
Azienda Ospedaliera Universitaria "Federico II"

Laboratorio Dipartimento di Pediatria

Efficacy safety and tolerability of growth hormone in patients with amyotrophic lateral sclerosis as add-on therapy to Riluzole-Phase II
Azienda Ospedaliera Universitaria "Federico II"

AOU Federico II

ALD-104 - A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects 0 to 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO

U.O. di Oncoematologia

Efficacy of Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS)
Policlinico Universitario Campus Bio-Medico

U.O.C. Neurologia

Tolerability, Safety and Efficacy of Sigh During Non-invasive Mechanical Ventilation in Patients With Motor Neuron Disease - A Pilot Study
IRCCS Ospedale San Raffaele

U.O. di Neurologia

A Phase II, Randomised, Double-Blind, Placebo-Controlled Study Followed by a Continuing Open Label Study, to Verify the Efficacy and Safty of Intrathecal Administration of KP-100IT using NP022 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Institution: Information not provided - JP

Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht

Polikliniek Neuromusculaire Ziekten

HORIZON: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy - AT
Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy - AT
Institution: Information not provided - AT

Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells
Zaklad Patologii Ogolnej

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK
Institution: Information not provided - SK

MAGNET: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) -ES
Hospital Universitari de Bellvitge

IMCRELA: Impact of the combined treatment of the liposomated polyphenols curcula and resveratrol with dutasteride, in the clinical improvement of patients with ALS treated with riluzole -ES
Universidad Católica de Valencia San Vicente Mártir

Clínicas UCV

Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With Dutasteride on the Clinical Improvement of ALS Patients -ES
Universidad Católica de Valencia San Vicente Mártir

Facultad de Enfermería

OAK: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic Failure - ES
Institution: Information not provided - ES

MERIDIAN: A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) -ES
Institution: Information not provided - ES

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation - ES
Institution: Information not provided - ES

Phoenix: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) -ES
Institution: Information not provided - ES

ADORE: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis - ES
Institution: Information not provided - ES

A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia) - ES
Institution: Information not provided - ES

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis -ES
Institution: Information not provided - ES

A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) -ES
Institution: Information not provided - ES

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy -ES
Institution: Information not provided - ES

ADOREXT: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis -ES
Institution: Information not provided - ES

HIMALAYA: A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension -ES
Institution: Information not provided - ES

CARDINALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis -ES
Institution: Information not provided - ES

TCIM-ELAII: Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosis -ES
Hospital Clínico Universitario Virgen de la Arrixaca

Servicio de Hematología

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis - US
University of Kansas Medical Center Research Institute

Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History (Phase I) - US
Mayo Clinic Rochester

Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
Institution: Information not provided - US

Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure
Institution: Information not provided - US

Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS Currently Taking Riluzole
Institution: Information not provided - US

A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
Institution: Information not provided - US

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Institution: Information not provided - US

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
Institution: Information not provided - GB

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB
Institution: Information not provided - GB

A Phase II Pilot Single-arm Safety and Tolerability Study of ILB in Patients With Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS) -GB
University of Birmingham

Institute for cancer studies

MAGNET: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - SE
Institution: Information not provided - SE

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral Sclerosis - SE
Karolinska Institutet

Department of Clinical Neuroscience (CNS)

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - CH
Universitätsspital Inselspital

University Hospital Inselspital

ROCK-ALS : Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS - CH
Kantonsspital St. Gallen

Muskelzentrum/ ALS clinic

A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -AU
Institution: Information not provided - AU

A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -GB
Institution: Information not provided - AU

PIVOT-HD: A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)

Klinik für Neurologie

Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements -DE
Institution: Information not provided - DE

DIAN-TU: A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-part Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease -DE
Institution: Information not provided - DE

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE
Universitätsmedizin Göttingen

Klinik für Kinder- und Jugendmedizin

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease -DE
Universitäts-Kinderklinik am St. Josef-Hospital

CeSER - Centrum für Seltene Erkrankungen (ZSE) der Ruhr-Universität Bochum

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -FR
Institution: Information not provided - FR

A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease -FR
Institution: Information not provided - FR

Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements -FR
Institution: Information not provided - FR

DIAN-TU: A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-part Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease -FR
Institution: Information not provided - FR

NEUROHD: Neuroleptics and Huntington Disease. Comparison of Olanzapine, Tetrabenazine and Tiapride. A multicentric, Randomised, Controlled Study (Phase III) - FR
Faculté de Médecine de Créteil

Equipe "NeuroPsychologie Interventionnelle"

TRIHEP3: A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease - FR
Institut du Cerveau et de la Moelle épinière (ICM) - Hôpital Pitié-Salpêtrière

Institut du Cerveau et de la Moëlle épinière - INSERM U1127

REVHD : Metabolic Intervention Using Resveratrol in Patients With Huntington Disease
Institut du Cerveau et de la Moelle épinière (ICM) - Hôpital Pitié-Salpêtrière

Institut du Cerveau et de la Moëlle épinière - INSERM U1127